SLC6A3 and Parkinson disease: A study with an animal model of Parkinson’s disease showed that subsequent repeated intranasal administration of both enantiomers attenuated MPTP-induced reduction of DAT, although (R)-ketamine’s effect was more potent than that of (S)-ketamine [8].